Hercules Inc. faces two alternate slates for four board seats on its 13-member board, and Mario Gabelli, the company’s largest shareholder, wants the struggling chemicals manufacturer to remove its poison pill. But all may be just blowing smoke—no sources see a sale for $1 billion market cap Hercules anyway.
To read the entire story, you must be logged in.
Please log in now or register with us.
